{"id":20541,"date":"2024-06-05T04:30:00","date_gmt":"2024-06-05T08:30:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-participera-a-la-45e-conference-annuelle-goldman-sachs-global-healthcare\/"},"modified":"2024-06-05T04:30:00","modified_gmt":"2024-06-05T08:30:00","slug":"dbv-technologies-participera-a-la-45e-conference-annuelle-goldman-sachs-global-healthcare","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-participera-a-la-45e-conference-annuelle-goldman-sachs-global-healthcare\/","title":{"rendered":"DBV Technologies participera \u00e0 la 45e conf\u00e9rence annuelle Goldman Sachs Global Healthcare"},"content":{"rendered":"<div class=\"pr-date-globe\">June 05, 2024 16:30 ET<\/div>\n<p align=\"right\">Ch\u00e2tillon, France, le 5 juin &lpar;22&nbsp;:30 CEST) 2024 <\/p>\n<p align=\"justify\"><strong>DBV Technologies participera \u00e0 la 45e conf\u00e9rence annuelle Goldman Sachs Global Healthcare<\/strong><\/p>\n<p align=\"justify\">DBV Technologies &lpar;Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT\u2014CUSIP: 23306J101), soci\u00e9t\u00e9 biopharmaceutique au stade clinique sp\u00e9cialis\u00e9e dans les options de traitement des allergies alimentaires et d&rsquo;autres conditions immunologiques dont les besoins m\u00e9dicaux ne sont pas satisfaits, a annonc\u00e9 aujourd&rsquo;hui que Daniel Tass\u00e9, Directeur G\u00e9n\u00e9ral, participera \u00e0 une discussion \u00ab&nbsp;Fireside Chat&nbsp;\u00bb lors de la 45\u00e8me Conf\u00e9rence annuelle Goldman Sachs Global Healthcare, le lundi 10 juin \u00e0 8h00 &lpar;heure de l\u2019Est), ainsi qu&rsquo;\u00e0 des r\u00e9unions individuelles avec des investisseurs.<\/p>\n<p align=\"justify\">Une webdiffusion en direct de la pr\u00e9sentation est accessible <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Tis35vybBx9JwR4t8uXbYulCrT_haanPQ8WZcG_ujSRriWGTj1ANO2xCPWDxP7fvBlM3K9-AVkMpdbSS-mdF1_LiK6H2MalqK9lK4uF74fRcG9LiOyWhsOCJ0v1gaS4vW7Qx1s16MGEgZX7jI5GYmtPJ4OirzRB6HuWT7KkSgwpazqhaG_x19ShzSEzrvJhtfLdQwP-FCz74o5Rytr9qxOpUnSzbeCZ5s3Ue_r3WK7h8BTs6XL6tmlXWu7D3A76UP0KlQ370J0gF9It7yLGxT0cf2o8WEDJH4d1F0zDxZATRLSHfiFCNF8hGEKkI7KbAV7pMZ1drFOtW3_k3HN-zp9lgsvf6l73tE_01tAZfN2d9Vmwh3f-KPljv3WIKdkJT4rWO5f3yjnkk9YWqaj4-0A==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"ici\">ici<\/a> et sera \u00e9galement disponible sur la page \u00ab&nbsp;\u00c9v\u00e9nements&nbsp;\u00bb de la section \u00ab&nbsp;Investisseurs&nbsp;\u00bb du site Internet de la Soci\u00e9t\u00e9&nbsp;:&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QdAl14Kx-TB9QPKxs4ax397qmps2mdodmACGJwxePVdLcdzhP0qFIiMEeqBx8pTLdw51TjYJ_ZnNlm5JF_yh3PTCDjjkCfg75XWuS6-189ZKmMcqe8redGbhek3P2LF2jwfv8OaYJkAEuU4WfP_LPAaAAf2yXiw2UPhGSGADkSj_AYaBpVUUK4ntj_cAFGHfQAb9kcadM3kudJDgoeK7ZA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/dbv-technologies.com\/fr\/investor-overview\/evenements\/<\/a>.<\/p>\n<p align=\"left\">Une rediffusion sera \u00e9galement disponible pendant 90 jours apr\u00e8s chaque \u00e9v\u00e9nement.<\/p>\n<p align=\"justify\"><strong>\u00c0 propos de DBV Technologies<\/strong><br \/>DBV Technologies est une entreprise biopharmaceutique de stade clinique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019options de traitement des allergies alimentaires et autres affections immunologiques ayant d\u2019importants besoins m\u00e9dicaux non satisfaits. DBV Technologies se concentre actuellement sur l&rsquo;\u00e9tude de l&rsquo;utilisation de sa plateforme technologique exclusive, Viaskin\u2122, pour traiter les allergies alimentaires caus\u00e9es par une r\u00e9action immunitaire hypersensible et caract\u00e9ris\u00e9es par une gamme de sympt\u00f4mes dont la gravit\u00e9 varie de l\u00e9g\u00e8re \u00e0 l&rsquo;anaphylaxie potentiellement mortelle. Des millions de personnes vivent avec des allergies alimentaires, y compris de jeunes enfants. Gr\u00e2ce \u00e0 l&rsquo;immunoth\u00e9rapie \u00e9picutan\u00e9e &lpar;EPIT\u2122), la plateforme Viaskin est con\u00e7ue pour dispenser des quantit\u00e9s de microgrammes d&rsquo;un compos\u00e9 biologiquement actif dans le syst\u00e8me immunitaire \u00e0 travers une peau intacte. L&rsquo;EPIT est une nouvelle classe de traitement non invasif cherchant \u00e0 modifier l&rsquo;allergie sous-jacente d&rsquo;un individu en r\u00e9\u00e9duquant le syst\u00e8me immunitaire \u00e0 se d\u00e9sensibiliser \u00e0 l&rsquo;allerg\u00e8ne en tirant parti des propri\u00e9t\u00e9s de tol\u00e9rance immunitaire de la peau. DBV Technologies s&rsquo;est engag\u00e9e \u00e0 transformer le traitement des personnes souffrant d&rsquo;allergies alimentaires. Les programmes d&rsquo;allergie alimentaire de la Soci\u00e9t\u00e9 comprennent des \u00e9tudes cliniques en cours avec Viaskin Peanut chez les jeunes enfants &lpar;de 1 \u00e0 3 ans) et les enfants &lpar;de 4 \u00e0 7 ans) allergiques \u00e0 l&rsquo;arachide.<\/p>\n<p align=\"justify\">Le si\u00e8ge mondial de DBV Technologies est situ\u00e9 \u00e0 Ch\u00e2tillon, en France, avec des op\u00e9rations nord-am\u00e9ricaines bas\u00e9es \u00e0 Warren, dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris &lpar;symbole : DBV, code ISIN : FR0010417345) et les ADS de la Soci\u00e9t\u00e9 &lpar;chacun repr\u00e9sentant une demi-action ordinaire) sont n\u00e9goci\u00e9s sur le Nasdaq Stock Market &lpar;symbole: DBVT\u2014 CUSIP: 23306J101).<\/p>\n<p align=\"justify\">Pour plus d\u2019informations, veuillez consulter <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LE8E2b0cQ7vrxu8b3EnSooDPACyeCB3Cw6bpm4jWX1q4XKoZbbIna2i8_oEdTzmyvvt3x-6G3CbyFHNNdogGS5Wq0yac3UbcdLMCO6u6H6i4JqFdnR-k1Rg_B7L-6RDD\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.dbv-technologies.com\">www.dbv-technologies.com<\/a> et nous contacter sur <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F6pe2UOxltogN-tUMIcjeScOr-VBjJ7oco24fSoPcy1Ri9ifpbTzOUij9_C13VkTkbMOFletRyO5tbIBSikaOAAfMGbbBEvOw3UYbMXaATa5NBvRzqrSYlNR9sRflvDY\" rel=\"nofollow noopener\" target=\"_blank\" title=\"X &lpar;anciennement Twitter)\">X &lpar;anciennement Twitter)<\/a> et <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7KIErL48siBZ1bW70jnPACgH5qEk0ECJqmp-sLOO92IbL-tWzoUXBQcx8EvSyrlxX5ZFt65SZ1r2VYMyJtlV2rINMS87WvuhRQkccr5nH0MOODeGs2d1Q4yasJ_ry-m8\" rel=\"nofollow noopener\" target=\"_blank\" title=\"LinkedIn.\">LinkedIn.<\/a><\/p>\n<p align=\"justify\">Viaskin et EPIT sont des marques commerciales de DBV Technologies.<\/p>\n<p align=\"justify\"><strong>Contact avec les investisseurs <\/strong><br \/>Katie Matthews<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=agBTQrzjz_mLIIXOKxQ2yZZwxvp-63SvT_f5lSf_8xVI29CZh4MkWj0rv64tF6j_-98SjqGEf-twj98IINaiWhQdPuLCIWvS08XQj1y9Hb6ogleE28up48fMnClzw6oUZvHu3lB0jdlDblCyPj-_Yw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"katie.matthews@dbv-technologies.com\">katie.matthews@dbv-technologies.com<\/a><\/p>\n<p align=\"justify\"><strong>Contact avec les m\u00e9dias<\/strong><br \/>Angela Marcucci<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nDEwSk1EY632lxTd_7jJlniz0aZJGYqFWQiqBS2d1E33t-ctkRSTn9moJtDi2m1BabKBG-S1i_-Lbs7lsg5x-PxV6b7c3HduUyfmjlRAzJ_r8-nl66ReAcPlfk_x0Tzukt1tts-OvWxIMarvLIf6-Q==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"angela.marcucci@dbv-technologies.com\">angela.marcucci@dbv-technologies.com<\/a><\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=Qh6qf6k2nqBZVJr0453BaJxNQ9IAniKfvAVWOi8EtwSlEFbx1LfD8EaHCO5pasrJjm01biH3ggeCFN3YY18kJzHLUkTB5YyHUMuJV3FqP1SKEWB2kOGmm6-zoMy6UjNKk-cFcUMI4RKsZ6SY5yYhEn2ezs4ksJ0MZsEpo1-E2AA=\" title=\"version PDF\" rel=\"nofollow noopener\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/NDMyMzE0NTUtN2M2ZS00Nzc5LTljNWItNjI4MWJmOWE0Yzg2LTEwMTExNTI=\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">            <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[],"class_list":["post-20541","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/20541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/20541\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=20541"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=20541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}